CD8A and triple-negative breast carcinoma: Furthermore, the CD4/CD8 ratio is in some cancer types, like the triple negative breast cancer, a useful prognostic tool [10], but can also be used as indicator to monitor the course of a therapy with immune checkpoint inhibitors [11].